|Day's range||21.99 - 21.99|
RAHWAY, N.J., March 27, 2023--KEYTRUDA® Plus Chemotherapy Significantly Improved PFS Compared to Chemo Alone as 1L Therapy for Advanced or Recurrent Endometrial Carcinoma
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton are part of the Zacks top Analyst Blog.